long-term overall survival of aya patients with all who complete therapy on dfci consortium trials
Published 1 year ago • 60 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
2:49
orthopedic adverse events among aya patients with all treated with asparaginase
-
1:38
how overall survival and primary causes of death have changed in patients with al amyloidosis
-
0:56
real-world survival in patients with mixed phenotype attr-cm treated with tafamidis
-
1:48
overall survival by idh2 mutant allele in late-stage r/r aml patients enrolled in idhentify
-
1:40
long-term follow-up of the tourmaline-mm1 trial
-
3:19
analysis of long-term survival in a large apl patient cohort: a harmony alliance study
-
2:42
approaches to treating elderly patients with all: the role of tkis and antibody therapies
-
0:49
exploring novel treatment strategies for ph-like all
-
2:24
novel all treatment strategies: blinatumomab
-
2:09
an overview of the management of patients with r/r waldenström’s macroglobulinemia
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
4:43
novel treatments being explored for patients with hemophilia: highlights from isth 2024
-
5:46
improved survival for adult acute lymphoblastic leukemia (all) patients
-
1:22
combination therapies and their role in the all treatment landscape
-
2:10
updated overall survival data on eltanexor for hma-refractory mds
-
5:47
hovon146all: blinatumomab added to prephase and consolidation therapy in precursor b-all
-
3:36
outcomes of patients with newly diagnosed crlf2-rearranged b-all
-
1:22
long-term follow-up results of tourmaline-mm2: ird vs pbo-rd in multiple myeloma
-
3:30
clinical value of event-free survival in aml